Quick Answer
Bicara Therapeutics Inc. reported Net Income of -$137.95 million for fiscal year 2025.
Bicara Therapeutics Inc. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|
| Net Income | -$137.95M -102.9% |
-$68.00M -30.8% |
-$51.98M | — |
| Diluted EPS | -$2.52 +37.8% |
-$4.05 +95.5% |
-$89.61 | — |
| Total Assets | $430.99M -15.5% |
$510.00M +118.0% |
$233.98M | — |
| Cash and Equivalents | $96.69M -80.3% |
$489.71M +112.5% |
$230.44M | — |
| Stockholders Equity | $401.45M -18.4% |
$491.88M +430.6% |
-$148.77M -50.6% |
-$98.80M |
| R&D Expense | — | $63.60M +107.8% |
$30.60M | — |
| Operating Income | -$155.60M -88.9% |
-$82.39M -106.5% |
-$39.89M | — |
| Shares Outstanding | 56.60M +4.0% |
54.44M +8401.1% |
640,386 | — |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Net Income | September 30, 2025 | -$36.33M | -107.8% | -32.6% |
| Diluted EPS | September 30, 2025 | -$0.67 | +58.1% | -34.0% |
| Total Assets | September 30, 2025 | $424.69M | -19.0% | -6.4% |
| Cash and Equivalents | September 30, 2025 | $171.67M | -67.0% | -60.7% |
| Stockholders Equity | September 30, 2025 | $402.78M | -21.0% | -7.4% |
| R&D Expense | September 30, 2025 | $33.00M | +107.5% | +33.1% |
| Operating Income | September 30, 2025 | -$40.68M | -97.2% | -27.0% |
| Shares Outstanding | September 30, 2025 | 54.61M | +0.4% | +0.1% |
- Bicara Therapeutics Inc. reported Net Income of -$137.95 million for fiscal year 2025.
- Bicara Therapeutics Inc. showed a decrease of -102.9% in Net Income compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Diluted EPS of $2.52 per share (loss) for fiscal year 2025.
- Bicara Therapeutics Inc. showed an increase of +37.8% in Diluted EPS compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Total Assets of $430.99 million for fiscal year 2025.
- Bicara Therapeutics Inc. showed a decrease of -15.5% in Total Assets compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Cash and Equivalents of $96.69 million for fiscal year 2025.
- Bicara Therapeutics Inc. showed a decrease of -80.3% in Cash and Equivalents compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Stockholders Equity of $401.45 million for fiscal year 2025.
- Bicara Therapeutics Inc. showed a decrease of -18.4% in Stockholders Equity compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported R&D Expense of $63.60 million for fiscal year 2024.
- Bicara Therapeutics Inc. showed an increase of +107.8% in R&D Expense compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Operating Income of -$155.60 million for fiscal year 2025.
- Bicara Therapeutics Inc. showed a decrease of -88.9% in Operating Income compared to the prior fiscal year.
- Bicara Therapeutics Inc. reported Shares Outstanding of 56.60 million shares for fiscal year 2025.
- Bicara Therapeutics Inc. showed an increase of +4.0% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: